PM54 plus immunotherapy for advanced cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called PM54 combined with pembrolizumab (an immunotherapy) in people with advanced cancers that have gotten worse despite prior treatment. The goal is to see if this combination can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of advanced cancer (spread, relapsed, or metastatic) that cannot be cured with surgery or radiation alone
- Your cancer has gotten worse on or after at least one prior chemotherapy or treatment regimen
- Your overall health is good enough for treatment (ECOG performance status 0 or 1, meaning you can do most normal activities)
- Your blood counts, liver, and kidney function meet acceptable levels (specific lab tests within 7 days of starting)
- You have recovered from effects of prior surgery, radiation, or chemotherapy, with no severe lingering side effects
- You are willing to use effective birth control during treatment and for several months after (if applicable) and comply with all trial procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
This early-phase study tests PM534 given through an IV to see if it is safe and how well it works in people with advanced solid tumors. It may help by finding a new treatment option, but eligibility is strict to protect participants from side effects.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.